iosBio believes that thermally stable, self-administered vaccines in capsule form are the future. Due to its OraPro™ platform, these are inexpensive to produce, developed in weeks and, following regulatory approval, can be distributed by mail.
iosBio is using this approach to tackle the global COVID-19 pandemic, developing a capsule-based vaccine that could be easily distributed to millions across the globe. This comes afte...
iosBio believes that thermally stable, self-administered vaccines in capsule form are the future. Due to its OraPro™ platform, these are inexpensive to produce, developed in weeks and, following regulatory approval, can be distributed by mail.
iosBio is using this approach to tackle the global COVID-19 pandemic, developing a capsule-based vaccine that could be easily distributed to millions across the globe. This comes after successfully working on an oral vaccine for the Zika virus.
iosBio’s OraPro™ technology means these thermally stable viral vector-based vaccines can be delivered in capsule form to the GI tract.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.